167 related articles for article (PubMed ID: 30105268)
1. The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer.
Kurtenkov O; Innos K; Sergejev B; Klaamas K
Biomed Res Int; 2018; 2018():9579828. PubMed ID: 30105268
[TBL] [Abstract][Full Text] [Related]
2. Signatures of anti-Thomsen - Friedenreich antigen antibody diversity in colon cancer patients.
Kurtenkov O; Bubina M; Klaamas K
Exp Oncol; 2018 Mar; 40(1):48-58. PubMed ID: 29600973
[TBL] [Abstract][Full Text] [Related]
3. Increased Avidity of the Sambucus nigra Lectin-Reactive Antibodies to the Thomsen-Friedenreich Antigen as a Potential Biomarker for Gastric Cancer.
Kurtenkov O; Klaamas K
Dis Markers; 2015; 2015():761908. PubMed ID: 26663951
[TBL] [Abstract][Full Text] [Related]
4. Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential.
Kurtenkov O; Izotova J; Klaamas K; Sergeyev B
Biomed Res Int; 2014; 2014():830847. PubMed ID: 25276822
[TBL] [Abstract][Full Text] [Related]
5. Hidden IgG Antibodies to the Tumor-Associated Thomsen-Friedenreich Antigen in Gastric Cancer Patients: Lectin Reactivity, Avidity, and Clinical Relevance.
Kurtenkov O; Klaamas K
Biomed Res Int; 2017; 2017():6097647. PubMed ID: 28316982
[TBL] [Abstract][Full Text] [Related]
6. Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients.
Kodar K; Izotova J; Klaamas K; Sergeyev B; Järvekülg L; Kurtenkov O
World J Gastroenterol; 2013 Jun; 19(23):3573-82. PubMed ID: 23801858
[TBL] [Abstract][Full Text] [Related]
7. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen.
MacLean GD; Bowen-Yacyshyn MB; Samuel J; Meikle A; Stuart G; Nation J; Poppema S; Jerry M; Koganty R; Wong T
J Immunother (1991); 1992 May; 11(4):292-305. PubMed ID: 1599915
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen.
Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Sommer H; Friese K
Histochem Cell Biol; 2005 Jun; 123(6):631-7. PubMed ID: 15889266
[TBL] [Abstract][Full Text] [Related]
9. The Thomsen-Friedenreich antigen and alphaGal-specific human IgG glycoforms: concanavalin A reactivity and relation to survival of cancer patients.
Kodar K; Kurtenkov O; Klaamas K
Immunol Invest; 2009; 38(8):704-17. PubMed ID: 19860583
[TBL] [Abstract][Full Text] [Related]
10. Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential.
Kurtenkov O
Biomed Res Int; 2020; 2020():9747040. PubMed ID: 32280709
[TBL] [Abstract][Full Text] [Related]
11. Anti-Thomsen-Friedenreich (T) antibody-based ELISA and its application to human breast carcinoma detection.
Desai PR; Ujjainwala LH; Carlstedt SC; Springer GF
J Immunol Methods; 1995 Dec; 188(2):175-85. PubMed ID: 8551046
[TBL] [Abstract][Full Text] [Related]
12. Thomsen-Friedenreich and Tn antigens in nipple fluid: carbohydrate biomarkers for breast cancer detection.
Kumar SR; Sauter ER; Quinn TP; Deutscher SL
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6868-71. PubMed ID: 16203776
[TBL] [Abstract][Full Text] [Related]
13. IgG immune response to tumor-associated carbohydrate antigens (TF, Tn, alphaGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival.
Kurtenkov O; Klaamas K; Rittenhouse-Olson K; Vahter L; Sergejev B; Miljukhina L; Shljapnikova L
Exp Oncol; 2005 Jun; 27(2):136-40. PubMed ID: 15995632
[TBL] [Abstract][Full Text] [Related]
14. The presence and significance of the Thomsen-Friedenreich antigen in breast cancer. I. Serological studies.
Newman RA; Klein PJ; Uhlenbruck G; Citoler P; Karduck D
J Cancer Res Clin Oncol; 1979 Feb; 93(2):181-8. PubMed ID: 374421
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of Thomsen-Friedenreich antigens during tumor progression in breast cancer patients.
Wolf MF; Ludwig A; Fritz P; Schumacher K
Tumour Biol; 1988; 9(4):190-4. PubMed ID: 3420374
[TBL] [Abstract][Full Text] [Related]
16. Postoperative change of anti-Thomsen-Friedenreich and Tn IgG level: the follow-up study of gastrointestinal cancer patients.
Smorodin EP; Kurtenkov OA; Sergeyev BL; Kodar KE; Chuzmarov VI; Afanasyev VP
World J Gastroenterol; 2008 Jul; 14(27):4352-8. PubMed ID: 18666325
[TBL] [Abstract][Full Text] [Related]
17. [ELISA of IgM antibodies to Thomsen-Friedenreich (TF) hapten in cancer diagnostics: comparison of data obtained with four TF-glycoconjugates].
Smorodin EP; Jansson B; Miliukhina L; Paaski G; Bovin NV; Ovchinnikova TV; Kurtenkov O
Bioorg Khim; 1997 Oct; 23(10):795-9. PubMed ID: 9490614
[TBL] [Abstract][Full Text] [Related]
18. Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen.
Schindlbeck C; Stellwagen J; Jeschke U; Karsten U; Rack B; Janni W; Jückstock J; Tulusan A; Sommer H; Friese K
Clin Exp Metastasis; 2008; 25(3):233-40. PubMed ID: 18185913
[TBL] [Abstract][Full Text] [Related]
19. Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin.
Campbell BJ; Finnie IA; Hounsell EF; Rhodes JM
J Clin Invest; 1995 Feb; 95(2):571-6. PubMed ID: 7860740
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients.
Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Krajewski S; Sommer H; Friese K
Breast Cancer Res Treat; 2007 Jan; 101(1):17-25. PubMed ID: 16807671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
